Abstract

Patients with type 2 diabetes (T2D) are characterized by blunted immune responses, which are affected by glycaemic control. Whether glycaemic control influences the response to COVID-19 vaccines and the incidence of SARS-CoV-2 breakthrough infections is unknown. Here we show that poor glycaemic control, assessed as mean HbA1c in the post-vaccination period, is associated with lower immune responses and an increased incidence of SARS-CoV-2 breakthrough infections in T2D patients vaccinated with mRNA-BNT162b2. We report data from a prospective observational study enroling healthcare and educator workers with T2D receiving the mRNA-BNT162b2 vaccine in Campania (Italy) and followed for one year (5 visits, follow-up 346 ± 49 days) after one full vaccination cycle. Considering the 494 subjects completing the study, patients with good glycaemic control (HbA1c one-year mean < 7%) show a higher virus-neutralizing antibody capacity and a better CD4 + T/cytokine response, compared with those with poor control (HbA1c one-year mean ≥ 7%). The one-year mean of HbA1c is linearly associated with the incidence of breakthrough infections (Beta = 0.068; 95% confidence interval [CI], 0.032-0.103; p < 0.001). The comparison of patients with poor and good glycaemic control through Cox regression also show an increased risk for patients with poor control (adjusted hazard ratio [HR], 0.261; 95% CI, 0.097-0.700; p = 0.008). Among other factors, only smoking (HR = 0.290, CI 0.146-0.576 for non-smokers; p < 0.001) and sex (HR = 0.105, CI 0.035-0.317 for females; p < 0.001) are significantly associated with the incidence of breakthrough infections.

In this study, Marfella et al. show that patients with diabetes and poor glycaemic control have a blunted response to COVID-19 vaccine and are more prone to develop breakthrough infections, with further analysis suggesting smoking and male sex as potential risk factors to get COVID-19 despite vaccination.

Details

Title
Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes
Author
Marfella Raffaele 1   VIAFID ORCID Logo  ; Sardu Celestino 2 ; D’Onofrio Nunzia 2 ; Prattichizzo Francesco 3   VIAFID ORCID Logo  ; Scisciola Lucia 2 ; Messina, Vincenzo 4 ; La Grotta Rosalba 3 ; Balestrieri, Maria Luisa 2 ; Maggi, Paolo 2 ; Napoli, Claudio 2 ; Ceriello Antonio 3 ; Paolisso Giuseppe 1 

 Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy (GRID:grid.9841.4) (ISNI:0000 0001 2200 8888); Mediterranea Cardiocentro, Naples, Italy (GRID:grid.477084.8) (ISNI:0000 0004 1787 3414) 
 Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy (GRID:grid.9841.4) (ISNI:0000 0001 2200 8888) 
 IRCCS MultiMedica, Milan, Italy (GRID:grid.420421.1) (ISNI:0000 0004 1784 7240) 
 Sant’Anna Hospital, Caserta, Italy (GRID:grid.9841.4) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2656442828
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.